GENERATION OF CAR MODIFIERS FOR TUMOR TREATMENT
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Nov 14, 2024
app pub date -
Mar 13, 2024
filing date -
Mar 13, 2024
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present disclosure provides modified immune cells or precursors thereof (e.g. T cells) comprising a first chimeric antigen receptor (CAR) capable of binding human IL13Rα2, a second CAR capable of binding EGFR or an isoform thereof, and a dominant negative TGFβ type II receptor (DN-TGFβRII). Compositions and methods of treatment are also provided.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully